Report Detail

Pharma & Healthcare Global Imatinib Drug Market Insights, Forecast to 2025

  • RnM2341297
  • |
  • 14 June, 2019
  • |
  • Global
  • |
  • 112 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases.

Growth in prevalence of cancer, increase in demand for target drug therapy, and patent expiry of imatinib drug are expected to drive the imatinib drug market. Furthermore, rise in healthcare expenditure and increase in awareness of cancer by government and private organizations are anticipated to boost the market growth.
The global Imatinib Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Imatinib Drug market based on company, product type, end user and key regions.

This report studies the global market size of Imatinib Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Imatinib Drug in these regions.
This research report categorizes the global Imatinib Drug market by top players/brands, region, type and end user. This report also studies the global Imatinib Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novartis
Glenmark Pharmaceuticals Ltd.
Sun Pharmaceuticals
Actavis Generics
Dr. Reddy's Laboratories
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Cipla Inc.
Apotex Inc.
Mylan Pharms Inc.

Market size by Product
Tablets
Capsules
Market size by End User
Chronic myelogenous leukemia
Gastrointestinal stromal tumors
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Imatinib Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Imatinib Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Imatinib Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Imatinib Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Imatinib Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Imatinib Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Study Coverage

    • 1.1 Imatinib Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Imatinib Drug Market Size Growth Rate by Product
      • 1.4.2 Tablets
      • 1.4.3 Capsules
    • 1.5 Market by End User
      • 1.5.1 Global Imatinib Drug Market Size Growth Rate by End User
      • 1.5.2 Chronic myelogenous leukemia
      • 1.5.3 Gastrointestinal stromal tumors
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Imatinib Drug Market Size
      • 2.1.1 Global Imatinib Drug Revenue 2014-2025
      • 2.1.2 Global Imatinib Drug Sales 2014-2025
    • 2.2 Imatinib Drug Growth Rate by Regions
      • 2.2.1 Global Imatinib Drug Sales by Regions
      • 2.2.2 Global Imatinib Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Imatinib Drug Sales by Manufacturers
      • 3.1.1 Imatinib Drug Sales by Manufacturers
      • 3.1.2 Imatinib Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Imatinib Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Imatinib Drug Revenue by Manufacturers
      • 3.2.1 Imatinib Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Imatinib Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Imatinib Drug Price by Manufacturers
    • 3.4 Imatinib Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Imatinib Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Imatinib Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Imatinib Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Imatinib Drug Sales by Product
    • 4.2 Global Imatinib Drug Revenue by Product
    • 4.3 Imatinib Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Imatinib Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Imatinib Drug by Countries
      • 6.1.1 North America Imatinib Drug Sales by Countries
      • 6.1.2 North America Imatinib Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Imatinib Drug by Product
    • 6.3 North America Imatinib Drug by End User

    7 Europe

    • 7.1 Europe Imatinib Drug by Countries
      • 7.1.1 Europe Imatinib Drug Sales by Countries
      • 7.1.2 Europe Imatinib Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Imatinib Drug by Product
    • 7.3 Europe Imatinib Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Imatinib Drug by Countries
      • 8.1.1 Asia Pacific Imatinib Drug Sales by Countries
      • 8.1.2 Asia Pacific Imatinib Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Imatinib Drug by Product
    • 8.3 Asia Pacific Imatinib Drug by End User

    9 Central & South America

    • 9.1 Central & South America Imatinib Drug by Countries
      • 9.1.1 Central & South America Imatinib Drug Sales by Countries
      • 9.1.2 Central & South America Imatinib Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Imatinib Drug by Product
    • 9.3 Central & South America Imatinib Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Imatinib Drug by Countries
      • 10.1.1 Middle East and Africa Imatinib Drug Sales by Countries
      • 10.1.2 Middle East and Africa Imatinib Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Imatinib Drug by Product
    • 10.3 Middle East and Africa Imatinib Drug by End User

    11 Company Profiles

    • 11.1 Novartis
      • 11.1.1 Novartis Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Novartis Imatinib Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Novartis Imatinib Drug Products Offered
      • 11.1.5 Novartis Recent Development
    • 11.2 Glenmark Pharmaceuticals Ltd.
      • 11.2.1 Glenmark Pharmaceuticals Ltd. Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Glenmark Pharmaceuticals Ltd. Imatinib Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Glenmark Pharmaceuticals Ltd. Imatinib Drug Products Offered
      • 11.2.5 Glenmark Pharmaceuticals Ltd. Recent Development
    • 11.3 Sun Pharmaceuticals
      • 11.3.1 Sun Pharmaceuticals Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Sun Pharmaceuticals Imatinib Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Sun Pharmaceuticals Imatinib Drug Products Offered
      • 11.3.5 Sun Pharmaceuticals Recent Development
    • 11.4 Actavis Generics
      • 11.4.1 Actavis Generics Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Actavis Generics Imatinib Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Actavis Generics Imatinib Drug Products Offered
      • 11.4.5 Actavis Generics Recent Development
    • 11.5 Dr. Reddy's Laboratories
      • 11.5.1 Dr. Reddy's Laboratories Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Dr. Reddy's Laboratories Imatinib Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Dr. Reddy's Laboratories Imatinib Drug Products Offered
      • 11.5.5 Dr. Reddy's Laboratories Recent Development
    • 11.6 Teva Pharmaceutical Industries Ltd.
      • 11.6.1 Teva Pharmaceutical Industries Ltd. Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Teva Pharmaceutical Industries Ltd. Imatinib Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Teva Pharmaceutical Industries Ltd. Imatinib Drug Products Offered
      • 11.6.5 Teva Pharmaceutical Industries Ltd. Recent Development
    • 11.7 Sanofi S.A.
      • 11.7.1 Sanofi S.A. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Sanofi S.A. Imatinib Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Sanofi S.A. Imatinib Drug Products Offered
      • 11.7.5 Sanofi S.A. Recent Development
    • 11.8 Cipla Inc.
      • 11.8.1 Cipla Inc. Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Cipla Inc. Imatinib Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Cipla Inc. Imatinib Drug Products Offered
      • 11.8.5 Cipla Inc. Recent Development
    • 11.9 Apotex Inc.
      • 11.9.1 Apotex Inc. Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Apotex Inc. Imatinib Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Apotex Inc. Imatinib Drug Products Offered
      • 11.9.5 Apotex Inc. Recent Development
    • 11.10 Mylan Pharms Inc.
      • 11.10.1 Mylan Pharms Inc. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Mylan Pharms Inc. Imatinib Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Mylan Pharms Inc. Imatinib Drug Products Offered
      • 11.10.5 Mylan Pharms Inc. Recent Development

    12 Future Forecast

    • 12.1 Imatinib Drug Market Forecast by Regions
      • 12.1.1 Global Imatinib Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Imatinib Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Imatinib Drug Market Forecast by Product
      • 12.2.1 Global Imatinib Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Imatinib Drug Revenue Forecast by Product 2019-2025
    • 12.3 Imatinib Drug Market Forecast by End User
    • 12.4 North America Imatinib Drug Forecast
    • 12.5 Europe Imatinib Drug Forecast
    • 12.6 Asia Pacific Imatinib Drug Forecast
    • 12.7 Central & South America Imatinib Drug Forecast
    • 12.8 Middle East and Africa Imatinib Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Imatinib Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Summary:
      Get latest Market Research Reports on Imatinib Drug . Industry analysis & Market Report on Imatinib Drug is a syndicated market report, published as Global Imatinib Drug Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Imatinib Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,088.80
      4,633.20
      6,177.60
      3,611.40
      5,417.10
      7,222.80
      590,265.00
      885,397.50
      1,180,530.00
      325,260.00
      487,890.00
      650,520.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report